Haircare, Salon Trends and Hair-Loss Science — 2026-09-08
Dyson has unveiled two new hair tools, the Airsmooth Dryer Brush and Corrale CoolShine, at IFA 2026, marking its first-ever dryer brush. In clinical news, a new oral hair loss pill, VDPHL01, demonstrated superiority over minoxidil and finasteride in Phase 2/3 trials, while Korean conglomerate Aekyung Industrial launched a new hair care division to target the growing scalp wellness market.
Haircare, Salon Trends and Hair-Loss Science — 2026-09-08
Top developments
Dyson Launches Airsmooth and Corrale CoolShine at IFA 2026
Dyson introduced its first-ever dryer brush, the Airsmooth, and a new straightener, the Corrale CoolShine, during a launch event in Berlin for IFA 2026 (September 4–8). The Airsmooth combines drying and styling to reduce heat damage, while the Corrale CoolShine focuses on shine without extreme heat. This expansion into the "dryer brush" category, previously dominated by brands like Shark and Revlon, signals Dyson’s strategy to capture a larger share of the high-end styling tool market by addressing consumer demand for faster, multi-functional routines

VDPHL01 Oral Pill Outperforms Minoxidil in Phase 2/3 Trials
A new investigational oral hair loss pill, VDPHL01, has cleared Phase 2/3 trials with results showing it outperformed both minoxidil and finasteride. Dr. Michael Gold, the study investigator, highlighted the drug's efficacy in promoting hair regrowth with potentially fewer side effects than current standards. This development is critical for the hair-loss science community as it represents one of the most significant breakthroughs in androgenetic alopecia treatment in recent years, offering a potential alternative to topical applications and existing oral medications

Aekyung Industrial Establishes Dedicated Hair Care Division
South Korean beauty giant Aekyung Industrial announced on September 5 the creation of a new business unit dedicated specifically to hair and scalp care products. The company aims to leverage its established brands, Keracys and Black Fore, to expand globally in the "scalp wellness" sector. This move reflects the broader industry shift where haircare is increasingly treated with the same rigor as skincare, driven by younger demographics (20-30s) seeking preventive care rather than just corrective treatments

K18 Releases FutureIQ Hair Longevity Serum
K18 has launched the FutureIQ Hair Longevity Serum, a new scalp treatment designed to address shedding, graying, and scalp aging. Early reviews from beauty editors suggest the product targets the biological aging of the scalp environment, aligning with the trend of "skinification" of haircare where scalp health is viewed as the foundation for hair quality. This launch competes directly with other biotech-driven scalp serums entering the market this fall

Local view
In Japan, Sisley Paris relaunched its scalp serum, the Hair Rituel Fortifying Serum for the Scalp Advanced, on September 1, priced at ¥40,700 for 60mL. The reformulation emphasizes advanced formulas for scalp density, reflecting the Japanese market's preference for high-efficacy, luxury scalp treatments. Meanwhile, Korean media highlights the rise of "brush-integrated" hair loss ampoules, such as those from brands popular in Olive Young, which are now expanding to the US market, catering to consumers seeking convenient, all-in-one scalp treatments.
Context & numbers
- Dyson Pricing & Positioning: The new Dyson tools enter a market where the existing Airwrap often retails around $600. Recent Labor Day sales saw the Airwrap discounted by $130, indicating competitive pressure on Dyson’s legacy products even as they launch new hardware.
- Market Segmentation: Korean reports indicate that the "special care" segment (scalp wellness, anti-aging, texture management) is growing faster than traditional shampoo/conditioner categories, driven by consumers under 40 who view scalp care as part of their daily skincare routine.
On the radar
- IFA 2026 Follow-ups: Keep an eye on independent reviews of the Dyson Airsmooth and Corrale CoolShine later this month, particularly regarding their heat-damage claims compared to the original Corrale.
- Clinical Trial Data Release: Full detailed datasets for the VDPHL01 Phase 2/3 trials are expected to be presented at upcoming dermatology conferences, which will clarify long-term safety profiles compared to finasteride.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.